- In November 2024, Axogen, Inc. announced that the U.S. Food and Drug Administration (FDA) accepted its Biologics License Application (BLA) for the Avance Nerve Graft
- In October 2024, Integra LifeSciences announced the launch of SurgiMend PRS Meshed Collagen Matrix, designed for plastic and reconstructive surgery. While this product is primarily indicated for soft tissue reconstruction, its collagen matrix technology may have implications for nerve repair applications, providing a scaffold that supports tissue regeneration
- In September 2024, Axogen, Inc. announced the completion of its Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for the Avance Nerve Graft. This submission marks a significant step in transitioning the Avance Nerve Graft from a tissue product to a biologic, aiming to enhance its regulatory standing and market reach
- In September 2024, Stryker Corporation announced the completion of its acquisition of NICO Corporation, a privately held company specializing in minimally invasive surgery for brain tumor removal and stroke care. This strategic acquisition is expected to enhance Stryker's capabilities in the nerve repair and regeneration market by integrating NICO's innovative technologies into its existing portfolio
- In January 2020, Medtronic received CE Mark for its InterStim Micro neurostimulator and InterStim SureScan MRI leads. The technologies are clear for commercial sale and clinical use in Europe and offer full-body MRI scan eligible and lifestyle-friendly choice
Frequently Asked Questions
The technological innovations in biomaterials for enhanced nerve regeneration, is emerging as a pivotal trend driving the global nerve repair biomaterials market.
The major factors driving the growth of the nerve repair biomaterials market are rising incidence of nerve injuries and increasing preference for advanced biomaterials and advancements in biomaterial technologies enhancing nerve regeneration outcomes
The primary challenges include high costs of nerve repair biomaterials impeding market growth and stringent regulatory requirements for product approvals and difficulties in treating large nerve gaps
The neuromodulation devices segment is expected to dominate the nerve repair biomaterials market with the largest share of 68.5% in 2025 due to their increasing use in treating nerve-related conditions, such as chronic pain and nerve injuries.
Asia-Pacific is expected to be the fastest growing region in the nerve repair biomaterials market with a market share of 26.5%, during the forecast period due to rapid expansion of healthcare infrastructure, growing healthcare awareness, and rising surgical volumes
